Tesamorelin 10mg — GHRH Analogue for Visceral Fat & Body Composition Research
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that holds the unique distinction of being FDA-approved (as Egrifta) for the treatment of excess visceral abdominal fat in HIV-positive adults with lipodystrophy. As a GHRH analogue, it stimulates the pituitary gland to release endogenous growth hormone in a pulsatile, physiological manner — making it highly relevant to researchers studying GH axis biology, body composition, visceral adiposity, and metabolic health.
Product Overview
Tesamorelin is a 44-amino acid synthetic peptide analogue of human GHRH (1-44), stabilized with a trans-3-hexenoic acid modification that enhances half-life. By stimulating endogenous GH release from the pituitary, tesamorelin drives IGF-1 production and activates the GH/IGF-1 axis — with documented effects on visceral fat reduction, lean mass preservation, lipid profile improvement, and metabolic health markers.
Key Benefits
- Visceral fat reduction — FDA-approved for visceral adiposity; extensively documented in clinical research
- GH/IGF-1 axis stimulation — pulsatile GH release mimicking physiological patterns
- Lean mass preservation — GH-mediated anabolic effects on muscle tissue
- Lipid profile improvement — improvements in triglycerides and cholesterol in clinical studies
- Liver fat reduction — studied for NAFLD and hepatic fat biology
- Cognitive function research — exploratory research in mild cognitive impairment
- Cardiovascular metabolic benefits — improves cardiovascular risk markers
Popular Use Cases
Tesamorelin research spans body composition science, visceral adiposity biology, NAFLD, and cognitive aging. Its FDA-approved status provides an exceptional clinical evidence base. Researchers studying GH axis biology and body composition changes in aging or metabolic disease will find tesamorelin uniquely well-documented.
Who Commonly Uses This
Endocrinologists, metabolic health researchers, body composition scientists, hepatologists, and cognitive aging researchers represent the primary communities for tesamorelin.
Product Details
| Peptide | Tesamorelin (GHRH analogue) |
| Content | 10mg per vial |
| Format | Lyophilized powder |
| BAC Water | Not included |
| Purity | ≥99% HPLC verified |
| Storage | 2–8°C, away from light |
| Research Use | For laboratory and research purposes only |
Storage & Handling
Store at 2–8°C away from light. Once reconstituted, refrigerate and use within 28–30 days.
Research & Scientific Interest
Tesamorelin’s clinical evidence base is exceptional. FDA-approved Phase III trials demonstrated ~15% visceral fat reduction, improvements in lipid profiles, and lean mass maintenance — all while stimulating GH in a pulsatile physiological manner. Research continues in NAFLD, cognitive function, and cardiovascular risk in aging populations.
Frequently Asked Questions
Tesamorelin is a synthetic GHRH analogue that stimulates pituitary GH release. FDA-approved for visceral fat in HIV lipodystrophy and researched for body composition, metabolic health, and GH/IGF-1 axis optimization.
By stimulating pulsatile GH release and elevating IGF-1, tesamorelin activates lipolysis in visceral adipose tissue. Clinical trials showed ~15% reduction in visceral fat.
Yes. Tesamorelin (Egrifta) is FDA-approved for excess visceral abdominal fat in HIV-positive adults with lipodystrophy.
Store at 2–8°C away from light. Once reconstituted, refrigerate and use within 28–30 days.
No. Strictly for laboratory and research purposes only.
Yes. H&J Pharma offers same-day shipping with next-day delivery across Vietnam.
Research References
- Falutz J, et al. “Effects of tesamorelin on adipose tissue.” NEJM. 2007. PubMed
- Falutz J, et al. “Metabolic effects of tesamorelin.” JAIDS. 2010. PubMed
- Dhindsa S, et al. “Tesamorelin reduces liver fat.” Clinical Gastroenterology. 2018. PubMed
- Fourman LT, et al. “Tesamorelin improves cognition.” CID. 2019. PubMed
- Stanley TL, et al. “Tesamorelin reduces liver fat in NAFLD.” JCEM. 2021.
- Prakash A, Bhattacharya S. “Tesamorelin in HIV lipodystrophy.” Drugs. 2012. PubMed
- Spoletini G, et al. “GHRH analogues in body composition.” Obesity Reviews. 2015.
- Muller EE, et al. “Neuroendocrine control of GH secretion.” Physiological Reviews. 1999. PubMed
- Teichman SL, et al. “CJC-1295 stimulates GH.” JCEM. 2006. PubMed
- Giustina A, Veldhuis JD. “Pathophysiology of GH neuroregulation.” Endocrine Reviews. 1998. PubMed
Lifestyle & Wellness Context
Tesamorelin’s exceptional FDA-approved evidence base makes it one of the most thoroughly validated GHRH analogues. H&J Pharma supplies Tesamorelin 10mg at research grade with same-day shipping across Vietnam.
Related Wellness Research Areas
Research on GH axis biology, visceral adiposity, body composition, NAFLD, cognitive aging, and metabolic health will find tesamorelin one of the most clinically validated research peptides.
Reviews
There are no reviews yet.